Lista de obras - Thorsten Zenz - Dominio Público Uruguay

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

artículo científico publicado en 2005

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

artículo científico publicado en 2011

A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia

artículo científico publicado en 2009

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

artículo científico publicado en 2010

Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells

artículo científico publicado en 2013

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach

article published in 2014

BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia

artículo científico publicado en 2009

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

artículo científico publicado en 2016

BRAF inhibition in refractory hairy-cell leukemia.

artículo científico publicado en 2012

BRAF inhibitor therapy in HCL.

artículo científico publicado en 2015

BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia

artículo científico publicado en 2014

BRAF mutations in chronic lymphocytic leukemia

artículo científico publicado en 2012

Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia ⬇️

artículo científico publicado el 1 de septiembre de 2010

Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.

artículo científico publicado en 2006

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness

artículo científico publicado en 2021

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

artículo científico publicado en 2012

Chronic lymphocytic leukemia and 13q14: miRs and more

artículo científico publicado en 2009

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

artículo científico publicado en 2008

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

artículo científico publicado en 2016

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

artículo científico publicado en 2016

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

artículo científico publicado en 2013

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

artículo científico publicado en 2010

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

artículo científico publicado en 2016

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

artículo científico publicado en 2009

Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis

artículo científico publicado en 2010

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

artículo científico publicado en 2020

Drug-perturbation-based stratification of blood cancer

artículo científico publicado en 2017

Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival

artículo científico publicado en 2016

Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia

artículo científico publicado en 2015

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial

artículo científico publicado en 2010

Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia

artículo científico publicado en 2013

Exhausting T cells in CLL.

artículo científico publicado en 2013

Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

artículo científico publicado en 2011

Extracellular vesicles in chronic lymphocytic leukemia

artículo científico publicado en 2013

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

artículo científico publicado en 2016

From pathogenesis to treatment of chronic lymphocytic leukaemia

artículo científico publicado en 2009

Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia

artículo científico publicado en 2009

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

artículo científico publicado en 2014

Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

artículo científico publicado en 2007

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

artículo científico

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling

artículo científico publicado en 2016

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

artículo científico publicado en 2021

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas

artículo científico publicado en 2012

High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay

artículo científico

IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms

artículo científico publicado en 2020

Importance of genetics in chronic lymphocytic leukemia ⬇️

artículo científico publicado el 23 de marzo de 2011

Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity

artículo científico publicado en 2015

Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2 ⬇️

artículo científico publicado el 6 de diciembre de 2010

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

artículo científico publicado en 2009

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

artículo científico publicado en 2014

Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications

scientific article published on May 2008

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

artículo científico publicado en 2008

More (on) prognostic factors in chronic lymphocytic leukemia

article published in 2009

Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).

artículo científico publicado en 2010

Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets.

artículo científico publicado en 2018

Mutational landscape and complexity in CLL.

artículo científico publicado en 2015

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.

artículo científico publicado en 2013

Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells

artículo científico publicado en 2015

Next-generation sequencing of cancer consensus genes in lymphoma

artículo científico publicado en 2013

Nurse-like cells show deregulated expression of genes involved in immunocompetence.

artículo científico publicado en 2011

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

artículo científico publicado en 2013

P53 and microRNAs in chronic lymphocytic leukemia

Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells.

artículo científico publicado en 2015

Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk

artículo científico publicado en 2010

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

artículo científico publicado en 2012

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

artículo científico publicado en 2017

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

artículo científico publicado en 2015

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

artículo científico publicado en 2012

Requirement for YAP1 signaling in myxoid liposarcoma

artículo científico publicado en 2019

Risk categories and refractory CLL in the era of chemoimmunotherapy

artículo científico publicado en 2012

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

artículo científico publicado en 2016

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia

artículo científico publicado en 2018

SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL).

artículo científico publicado en 2010

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

artículo científico publicado en 2010

Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling

artículo científico publicado en 2015

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

artículo científico publicado en 2009

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies

scientific article published on 13 May 2020

TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin

artículo científico publicado en 2018

TP53 mutation and survival in aggressive B cell lymphoma

artículo científico publicado en 2017

TP53 mutation and survival in chronic lymphocytic leukemia

artículo científico publicado en 2010

TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial

artículo científico publicado en 2013

TRRAP is essential for regulating the accumulation of mutant and wild-type p53 in lymphoma

artículo científico publicado en 2018

Targeted resequencing for analysis of clonal composition of recurrent gene mutations in chronic lymphocytic leukaemia

artículo científico publicado en 2013

Targeting the BRAF V600E mutation in multiple myeloma

artículo científico publicado en 2013

The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia.

artículo científico publicado en 2008

The proliferative history shapes the DNA methylome of B-cell tumors and predicts clinical outcome

artículo científico publicado en 2020

Therapy with the FCR regimen does not overcome chronic lymphocytic leukemia biology: aberrant p53 expression predicts response and survival

artículo científico publicado en 2009

Treatment resistance in chronic lymphocytic leukemia: the role of the p53 pathway

artículo científico publicado en 2009

Tumor-derived exosomes modulate PD-L1 expression in monocytes.

artículo científico publicado en 2017

Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia ⬇️

artículo científico publicado el 1 de enero de 2010

Lista de obras de Thorsten Zenz

188Re or 90Y-labelled anti-CD66 antibody as part of a dose-reduced conditioning regimen for patients with acute leukaemia or myelodysplastic syndrome over the age of 55: results of a phase I-II study

A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies

A novel paradigm to trigger apoptosis in chronic lymphocytic leukemia

Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial

Aminoferrocene-based prodrugs and their effects on human normal and cancer cells as well as bacterial cells

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach

BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia

BRAF inhibition in hairy cell leukemia with low-dose vemurafenib

BRAF inhibition in refractory hairy-cell leukemia.

BRAF inhibitor therapy in HCL.

BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia

BRAF mutations in chronic lymphocytic leukemia

Biological diversity and risk-adapted treatment of chronic lymphocytic leukemia ⬇️

Bone marrow transplantation nephropathy after an intensified conditioning regimen with radioimmunotherapy and allogeneic stem cell transplantation.

CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness

Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Chronic lymphocytic leukemia and 13q14: miRs and more

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition

Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia

Continued response off treatment after BRAF inhibition in refractory hairy cell leukemia

DNA damage-induced transcriptional program in CLL: biological and diagnostic implications for functional p53 testing.

DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial.

Detection of genomic aberrations in molecularly defined Burkitt's lymphoma by array-based, high resolution, single nucleotide polymorphism analysis

Dissecting intratumour heterogeneity of nodal B-cell lymphomas at the transcriptional, genetic and drug-response levels

Drug-perturbation-based stratification of blood cancer

Elucidation of tonic and activated B-cell receptor signaling in Burkitt's lymphoma provides insights into regulation of cell survival

Epigenetic silencing of miR-708 enhances NF-κB signaling in chronic lymphocytic leukemia

Epoetin alfa in patients with advanced-stage Hodgkin's lymphoma: results of the randomized placebo-controlled GHSG HD15EPO trial

Evolution of DNA methylation is linked to genetic aberrations in chronic lymphocytic leukemia

Exhausting T cells in CLL.

Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia

Extracellular vesicles in chronic lymphocytic leukemia

Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma

From pathogenesis to treatment of chronic lymphocytic leukaemia

Gene expression factors as predictors of genetic risk and survival in chronic lymphocytic leukemia

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial.

Genetics and risk-stratified approach to therapy in chronic lymphocytic leukemia

Genomic analysis of hairy cell leukemia identifies novel recurrent genetic alterations

HSP90 promotes Burkitt lymphoma cell survival by maintaining tonic B-cell receptor signaling

Hairy cell leukemia and COVID-19 adaptation of treatment guidelines

High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas

High-throughput detection of nuclear factor-kappaB activity using a sensitive oligo-based chemiluminescent enzyme-linked immunosorbent assay

IgCaller for reconstructing immunoglobulin gene rearrangements and oncogenic translocations from whole-genome sequencing in lymphoid neoplasms

Importance of genetics in chronic lymphocytic leukemia ⬇️

Improved synthesis of N-benzylaminoferrocene-based prodrugs and evaluation of their toxicity and antileukemic activity

Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2 ⬇️

Lenalidomide treatment of chronic lymphocytic leukaemia patients reduces regulatory T cells and induces Th17 T helper cells

MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis

Molecular diagnostics in chronic lymphocytic leukemia - pathogenetic and clinical implications

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

More (on) prognostic factors in chronic lymphocytic leukemia

Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL).

Multi-Omics Factor Analysis-a framework for unsupervised integration of multi-omics data sets.

Mutational landscape and complexity in CLL.

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG.

Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells

Next-generation sequencing of cancer consensus genes in lymphoma

Nurse-like cells show deregulated expression of genes involved in immunocompetence.

Overview of available p53 function tests in relation to TP53 and ATM gene alterations and chemoresistance in chronic lymphocytic leukemia

P53 and microRNAs in chronic lymphocytic leukemia

Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells.

Protein expression analysis of chronic lymphocytic leukemia defines the effect of genetic aberrations and uncovers a correlation of CDK4, P27 and P53 with hierarchical risk

Rapid response of biallelic BRAF V600E mutated hairy cell leukaemia to low dose vemurafenib.

Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice

Recurrent CDKN1B (p27) mutations in hairy cell leukemia

Recurrent mutation of the ID3 gene in Burkitt lymphoma identified by integrated genome, exome and transcriptome sequencing

Requirement for YAP1 signaling in myxoid liposarcoma

Risk categories and refractory CLL in the era of chemoimmunotherapy

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia

SYK carries no activating point mutations in patients with chronic lymphocytic leukaemia (CLL).

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia

Stromal cell-mediated glycolytic switch in CLL cells involves Notch-c-Myc signaling

Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group

Survey of ex vivo drug combination effects in chronic lymphocytic leukemia reveals synergistic drug effects and genetic dependencies

TNF receptor signaling is a driver of chronic lymphocytic leukemia that can be therapeutically targeted by the flavonoid wogonin

TP53 mutation and survival in aggressive B cell lymphoma